Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: Multicentre, open-label, phase II safety study

详细信息    查看全文

• 作者：Jordi Bruix ; Won-Young Tak ; Antonio Gasbarrini ; Arm ; o Santoro ; Massimo Colombo ; Ho-Yeong Lim ; Vincenzo Mazzaferro ; Reiner Wiest ; Mar¨ªa Reig ; Andrea Wagner ; Luigi Bolondi
• 关键词：Hepatocellular carcinoma ; Receptor kinase inhibition ; Regorafenib ; Safety ; Second line ; Tolerability
• 刊名：European Journal of Cancer
• 出版年：2013
• 出版时间：November, 2013
• 年：2013
• 卷：49
• 期：16
• 页码：3412-3419
• 全文大小：489 K

文摘

Purpose

We assessed the safety of the multikinase inhibitor regorafenib in patients with hepatocellular carcinoma (HCC) that had progressed following first-line sorafenib.

Patients and methods

Thirty-six patients with Barcelona Clinic Liver Cancer stage B or C HCC and preserved to mildly impaired liver function (Child-Pugh class A) received regorafenib 160 mg once daily in cycles of 3 weeks on/1 week off treatment until disease progression, unacceptable toxicity, death or patient/physician decision to discontinue. The primary end-point was safety; secondary end-points included efficacy (including time to progression and overall survival).

Results

The median treatment duration was 19.5 weeks (range 2-103). At data cutoff, three patients remained on treatment. Reasons for discontinuation were adverse events (n = 20), disease progression (n = 10), consent withdrawal (n = 2) and death (n = 1). Seventeen patients required dose reductions (mostly for adverse events [n = 15]); 35 patients had treatment interruption (mostly for adverse events [n = 32] or patient error [n = 11]). The most frequent treatment-related adverse events were hand-foot skin reaction (any grade n = 19; grade ?3 n = 5), diarrhoea (n = 19; n = 2), fatigue (n = 19; n = 6), hypothyroidism (n = 15; n = 0), anorexia (n = 13; n = 0), hypertension (n = 13; n = 1), nausea (n = 12; n = 0) and voice changes (n = 10; n = 0). Disease control was achieved in 26 patients (partial response n = 1; stable disease n = 25). Median time to progression was 4.3 months. Median overall survival was 13.8 months.

Conclusion

Regorafenib had acceptable tolerability and evidence of antitumour activity in patients with intermediate or advanced HCC that progressed following first-line sorafenib.